Eco Animal Health Group welcomes Dr. Joachim Hasenmaier to its Board as Non-Executive Director

– UK, New Malden –  ECO Animal Health Group plc (LON: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, today announced the appointment of Dr. Joachim Hasenmaier (DVM, Ph.D.) to its Board as a Non-Executive Director, with immediate effect.

“I am delighted to welcome Joachim as a Non-Executive Director to ECO. He has a wealth of sector and board experience, and I am confident that his strong track record of delivering sales growth and driving performance will be hugely beneficial to the growth of the Company. We are excited about what 2024 holds as we look to maximise the potential of our broad commercial and R&D portfolio and expand our business both organically and via new opportunities.” said Board Chairman, Dr. Andrew Jones.

About Dr. Joachim Hasenmaier

Dr. Joachim Hasenmaier is a highly experienced commercial leader with more than two decades in the international animal health industry. From 2001 to 2019 he held a variety of senior roles within the animal health division at Boehringer Ingelheim, concluding as a member of the Board of Managing Directors responsible for the entire animal health division. During this time he led successful transformation initiatives including the integration of the former Sanofi animal health business Merial, spearheaded key product launches, and supported rapid global growth and expansion.

Dr. Joachim Hasenmaier said: “ECO Animal Health is at a pivotal time in its development. The Company is well positioned to capitalise on the future growth opportunities offered by its innovative, focused pipeline of vaccines and biologics. I look forward to working closely with the Board to drive the next phase of growth as a sector-leading pioneer in animal health.”

Dr. Joachim Hasenmaier has also served as Chairman of the Board at IMV Technologies since 2022 and as a Member of the Supervisory Boards of Invetx. He served on the Board of NASDAQ-listed Heska before its acquisition by Mars Petcare. He also held senior positions at Hoechst Roussel Vet and McKinsey & Company.

Dr. Joachim Hasenmaier is a Doctor of Veterinary Medicine and holds a Ph.D. in Immunology from Ludwig-Maximillians University in Munich. has an MBA from Northwestern University, USA.

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorizations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin is a proprietary, patented medication that is effective against both respiratory and intestinal diseases in pigs and poultry.


- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.